Icosavax is a biotechnology company in Washington that focuses on developing safe and effective vaccines against infectious diseases. Founded 2017 in Seattle, Washington, United States by David Baker Ph.D, Neil King, Adam Simpson JD, it invests in early stage ventures. It is a developer of computationally designed virus-like particle vaccines that are intended to reduce serious infectious diseases, including Respiratory Syncytial Virus. The vaccine is being developed to protect older people from respiratory syncytial virus (RSV) diseases. The company believes that science and technology can and will continue to improve public health and that preventing infection is preferable to treating illness.
Documentaries, videos and podcasts
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.
- ImutexA medical company that developed an IIa-ready universal flu vaccine in England to prevent infections.